Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Sales and Divestitures: 2020-2025

Historic Gains from Sales and Divestitures for Legend Biotech (LEGN) over the last 4 years, with Jun 2025 value amounting to $250,000.

  • Legend Biotech's Gains from Sales and Divestitures rose 12400.00% to $250,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $250,000, marking a year-over-year increase of 12400.00%. This contributed to the annual value of $481,000 for FY2022, which is 50.62% down from last year.
  • Per Legend Biotech's latest filing, its Gains from Sales and Divestitures stood at $250,000 for Q2 2025, which was up 371.70% from $53,000 recorded in Q1 2025.
  • Over the past 5 years, Legend Biotech's Gains from Sales and Divestitures peaked at $977,000 during Q3 2021, and registered a low of $2,000 during Q1 2024.
  • For the 3-year period, Legend Biotech's Gains from Sales and Divestitures averaged around $93,500, with its median value being $64,000 (2023).
  • Per our database at Business Quant, Legend Biotech's Gains from Sales and Divestitures soared by 93,600.00% in 2021 and then plummeted by 99.18% in 2022.
  • Legend Biotech's Gains from Sales and Divestitures (Quarterly) stood at $977,000 in 2021, then plummeted by 99.18% to $481,000 in 2022, then surged by 2,687.50% to $223,000 in 2023, then plummeted by 99.10% to $2,000 in 2024, then surged by 12,400.00% to $250,000 in 2025.
  • Its Gains from Sales and Divestitures was $250,000 in Q2 2025, compared to $53,000 in Q1 2025 and $2,000 in Q3 2024.